Rebecca Roylance

10.0k total citations
77 papers, 2.6k citations indexed

About

Rebecca Roylance is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, Rebecca Roylance has authored 77 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 43 papers in Oncology, 31 papers in Molecular Biology and 30 papers in Cancer Research. Recurrent topics in Rebecca Roylance's work include Cancer Genomics and Diagnostics (21 papers), Advanced Breast Cancer Therapies (14 papers) and Genetic factors in colorectal cancer (13 papers). Rebecca Roylance is often cited by papers focused on Cancer Genomics and Diagnostics (21 papers), Advanced Breast Cancer Therapies (14 papers) and Genetic factors in colorectal cancer (13 papers). Rebecca Roylance collaborates with scholars based in United Kingdom, United States and Germany. Rebecca Roylance's co-authors include Patricia Gorman, Ian Tomlinson, Andrew M. Hanby, Sarah Halford, Denise Sheer, Andrew Rowan, Walter F. Bodmer, Stavroula Droufakou, Ian R. Hart and Vinay Deshmane and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nature Medicine and Journal of Clinical Oncology.

In The Last Decade

Rebecca Roylance

74 papers receiving 2.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Rebecca Roylance United Kingdom 28 1.2k 1.1k 966 856 471 77 2.6k
Pascal Bonnier France 31 895 0.7× 1.4k 1.4× 1.1k 1.1× 495 0.6× 331 0.7× 90 2.7k
Maria Isabel Achatz Brazil 26 1.6k 1.3× 1.6k 1.5× 1.1k 1.1× 559 0.7× 887 1.9× 115 3.2k
Ella Evron Israel 23 2.4k 2.0× 928 0.9× 850 0.9× 305 0.4× 510 1.1× 65 3.5k
Deborah Toppmeyer United States 26 1.1k 0.9× 2.3k 2.1× 1.2k 1.3× 388 0.5× 355 0.8× 94 3.4k
Sung‐Won Kim South Korea 27 924 0.8× 791 0.7× 704 0.7× 408 0.5× 864 1.8× 109 2.3k
Pierre O. Chappuis Switzerland 31 1.3k 1.1× 1.7k 1.6× 1.5k 1.5× 702 0.8× 1.4k 3.0× 107 3.6k
Helena R. Chang United States 27 683 0.6× 955 0.9× 1.1k 1.1× 498 0.6× 217 0.5× 69 2.3k
Amanda Hummer United States 35 718 0.6× 1.3k 1.3× 613 0.6× 487 0.6× 372 0.8× 46 3.5k
K Holli Finland 28 778 0.7× 1.8k 1.7× 1.3k 1.4× 468 0.5× 772 1.6× 47 3.0k
Dahish Ajarim Saudi Arabia 26 609 0.5× 1.4k 1.3× 527 0.5× 552 0.6× 175 0.4× 88 2.4k

Countries citing papers authored by Rebecca Roylance

Since Specialization
Citations

This map shows the geographic impact of Rebecca Roylance's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rebecca Roylance with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rebecca Roylance more than expected).

Fields of papers citing papers by Rebecca Roylance

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rebecca Roylance. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rebecca Roylance. The network helps show where Rebecca Roylance may publish in the future.

Co-authorship network of co-authors of Rebecca Roylance

This figure shows the co-authorship network connecting the top 25 collaborators of Rebecca Roylance. A scholar is included among the top collaborators of Rebecca Roylance based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rebecca Roylance. Rebecca Roylance is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Cutts, Ros, Sarah Hrebien, Aditi Gulati, et al.. (2024). Discriminating subtypes in advanced breast cancer with ctDNA methylation profiling.. Journal of Clinical Oncology. 42(16_suppl). 1013–1013.
2.
Kipps, Emma, Kenneth K. C. Man, Rebecca Roylance, et al.. (2024). The impact of inter-cycle treatment delays on 5-year all-cause mortality in early-stage breast cancer: A retrospective cohort study. European Journal of Cancer. 210. 114301–114301. 4 indexed citations
3.
4.
Bridgewater, John, et al.. (2023). Personalising monitoring for chemotherapy patients through predicting deterioration in renal and hepatic function. Cancer Medicine. 12(17). 17856–17865. 4 indexed citations
5.
Copson, Ellen, John E. Abraham, Jeremy Braybrooke, et al.. (2023). Expert UK consensus on the definition of high risk of recurrence in HER2-negative early breast cancer: A modified Delphi panel. The Breast. 72. 103582–103582. 1 indexed citations
6.
Kohut, Kelly, et al.. (2023). DCIS and LCIS: Are the Risk Factors for Developing In Situ Breast Cancer Different?. Cancers. 15(17). 4397–4397. 7 indexed citations
7.
Asghar, Uzma, et al.. (2022). Systematic Review of Molecular Biomarkers Predictive of Resistance to CDK4/6 Inhibition in Metastatic Breast Cancer. UCL Discovery (University College London). 58 indexed citations
8.
Wong, Yien Ning Sophia, Christopher C.T. Sng, Diego Ottaviani, et al.. (2021). Systemic Anti-Cancer Therapy and Metastatic Cancer Are Independent Mortality Risk Factors during Two UK Waves of the COVID-19 Pandemic at University College London Hospital. Cancers. 13(23). 6085–6085. 2 indexed citations
9.
Bulat, Iurie, H-T. Arkenau, Richard D. Baird, et al.. (2020). 278MO cfDNA analysis from phase I/II study of lerociclib (G1T38), a continuously dosed oral CDK4/6 inhibitor, with fulvestrant in HR+/HER2- advanced breast cancer patients. Annals of Oncology. 31. S351–S352. 4 indexed citations
10.
Battisti, Nicolò Matteo Luca, Belinda Kingston, Judy King, et al.. (2019). Palbociclib and endocrine therapy in heavily pretreated hormone receptor-positive HER2-negative advanced breast cancer: the UK Compassionate Access Programme experience. Breast Cancer Research and Treatment. 174(3). 731–740. 15 indexed citations
11.
Masannat, Yazan, Ehab Husain, Rebecca Roylance, et al.. (2018). Pleomorphic LCIS what do we know? A UK multicenter audit of pleomorphic lobular carcinoma in situ. The Breast. 38. 120–124. 22 indexed citations
12.
Duncan, Morvwen, Elisavet Moschopoulou, Jennifer Deane, et al.. (2017). Review of systematic reviews of non-pharmacological interventions to improve quality of life in cancer survivors. BMJ Open. 7(11). e015860–e015860. 136 indexed citations
13.
14.
Jamal‐Hanjani, Mariam, Roger A’Hern, Nicolai J. Birkbak, et al.. (2015). Extreme chromosomal instability forecasts improved outcome in ER-negative breast cancer: a prospective validation cohort study from the TACT trial. Annals of Oncology. 26(7). 1340–1346. 63 indexed citations
15.
A’Hern, Roger, Mariam Jamal‐Hanjani, Attila Marcell Szász, et al.. (2013). Taxane benefit in breast cancer—a role for grade and chromosomal stability. Nature Reviews Clinical Oncology. 10(6). 357–364. 32 indexed citations
16.
Lee, Alvin, Rebecca Roylance, Jil Sander, et al.. (2011). CERT depletion predicts chemotherapy benefit and mediates cytotoxic and polyploid‐specific cancer cell death through autophagy induction. The Journal of Pathology. 226(3). 482–494. 52 indexed citations
17.
Roylance, Rebecca, David Endesfelder, Patricia Gorman, et al.. (2011). Relationship of Extreme Chromosomal Instability with Long-term Survival in a Retrospective Analysis of Primary Breast Cancer. Cancer Epidemiology Biomarkers & Prevention. 20(10). 2183–2194. 133 indexed citations
18.
Tomlinson, Ian, Maryou B. Lambros, Rebecca Roylance, & Anne‐Marie Cleton‐Jansen. (2002). Loss of heterozygosity analysis: Practically and conceptually flawed?. Genes Chromosomes and Cancer. 34(4). 349–353. 61 indexed citations
19.
Halford, Sarah, et al.. (2000). Adjuvant mitozantrone chemotherapy in advanced prostate cancer. British Journal of Urology. 86(6). 675–680. 67 indexed citations
20.
Roylance, Rebecca, Patricia Gorman, William H. Harris, et al.. (1999). Comparative genomic hybridization of breast tumors stratified by histological grade reveals new insights into the biological progression of breast cancer.. PubMed. 59(7). 1433–6. 195 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Pascal Bonnier Breakdown of academic impact, for papers by Maria Isabel Achatz Breakdown of academic impact, for papers by Ella Evron Breakdown of academic impact, for papers by Deborah Toppmeyer Breakdown of academic impact, for papers by Sung‐Won Kim Breakdown of academic impact, for papers by Pierre O. Chappuis Breakdown of academic impact, for papers by Helena R. Chang Breakdown of academic impact, for papers by Amanda Hummer Breakdown of academic impact, for papers by K Holli Breakdown of academic impact, for papers by Dahish Ajarim
Rankless by CCL
2026